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Abstract
The epidemiology of Mycobacterium tuberculosis (Mtb) and M. africanum (Maf) suggest 
differences in their virulence, but the host immune profile to better understand the pathogenesis of 
tuberculosis (TB) have not been studied. We compared the transcriptomic and metabolic profiles 
between Mtb and Maf-infected TB cases to identify host biomarkers associated with lineages-
specific pathogenesis and response to anti-TB chemotherapy. Venous blood samples from Mtb- 
and Maf-infected patients obtained before and after anti-TB treatment were analysed for cell 
composition, gene expression and metabolic profiles. Prior to treatment, similar transcriptomic 
profiles were seen in Maf- and Mtb-infected patients. In contrast, post-treatment, over 1600 genes 
related to immune responses and metabolic diseases were differentially expressed between the 
groups. Notably, the upstream regulator hepatocyte nuclear factor 4-alpha (HNF4α), which 
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regulated 15% of these genes, was markedly enriched. Serum metabolic profiles were similar in 
both group pre-treatment, but the decline in pro-inflammatory metabolites post-treatment were 
most pronounced in Mtb-infected patients. Together, the differences in both peripheral blood 
transcriptomic and serum metabolic profiles between Maf- and Mtb-infected patients observed 
over the treatment period, might be indicative of intrinsic host factors related to susceptibility to 
TB and/or differential efficacy of the standard anti-TB treatment on the two lineages.
Introduction
Tuberculosis (TB) caused by lineages of the Mycobacterium tuberculosis (Mtb) complex 
(MTBC) remains a serious threat to public health globally. The MTBC comprises 
mycobacteria affecting humans and animals, amongst which Mtb and M. africanum (Maf) 
lineages are the most isolated in human. A plethora of studies have focused on the pathogen 
and shown distinct lineages within the MTBC; some lineages, such as Maf have evolved but 
remained region-specific, while others such as Mtb-Beijing and Mtb-Europe-America-Africa 
have successfully spread globally.1-3 In the Gambia, Maf West African type 2 causes up to 
40% of all TB despite its relatively low virulence compared to Mtb.4,5 Analysis of the Maf 
genome has shown significant differences compared with Mtb that support its low virulence. 
These include the high number of pseudogenes6, impaired secretion of the virulence-
associated protein early-secreted antigenic target 6 kDa (ESAT-6)7, and the high number of 
disrupted genes involved in bacterial carbohydrate, lipid and micronutrient metabolism.8
Few studies have investigated the human host response to different lineages of MTBC.9-11 
In particular, the response of patients infected with different MTBC lineages to anti-TB drug 
treatment has been scarcely investigated12-14 and remains controversial. It has been 
suggested that different MTBC lineages have different rates of acquisition of drug 
resistance-associated mutations,15,16 and variable time to culture conversion.14 It has also 
been shown that host genetics, rather than the etiologic pathogen, also plays a major role in 
determining the response to anti-TB treatment12. Previous data from our laboratory have 
shown that the proportions of activated MTBC-specific T-cells are similar between Maf- and 
Mtb-infected patients before treatment, but significantly higher post-treatment in Maf- 
compared to Mtb-infected patients.17 This difference, after allegedly successful TB 
treatment, warrants further investigation into the possible underlying mechanism(s).
Transcriptomic and metabolic profiling are highly useful approaches towards a better 
understanding of host and pathogen interactions in disease and health.18 Studies describing 
peripheral blood cell transcriptional profiles have provided significant insights into TB 
pathogenesis19-27 and novel biomarkers for diagnosis and monitoring of the response to TB 
treatment.19-21,23 In this study, we perform an exploratory evaluation of transcriptomic and 
metabolic profiles of subjects infected with two different lineages of MTBC, Maf and Mtb, 
before and after anti-TB therapy in order to determine differences in host factors and/or 
biological processes associated with disease pathology and response to treatment.
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Results
Study participants
Twenty-six HIV-negative TB patients with drug-sensitive bacterial isolates were included in 
this study. Following genotyping of sputum isolates, 12 patients were classified as Maf West 
African type 2 (lineage 6) infected and 14 as infected with Mtb Europe-America-Africa 
(lineage 4), as previously described.17 Both groups had similar age, sex and ethnic 
distributions (Table 1). Although the smear microscopy grade was significantly higher in 
Mtb- than Maf-infected patients (Table 1; p=0.012), there was no significant difference in 
the disease severity as shown by TB-related clinical parameters such as duration of cough, 
body mass index (BMI), skin-fold thickness and chest X-ray (CXR) score prior to treatment 
(Table 1; Figure 1). However, Mtb-infected patients showed greater improvement than Maf-
infected patients in all clinical parameters following a similar length of anti-TB therapy and 
this was significant for the CXR score (Table 1, Figure 1 D; p=0.046). Following treatment, 
the haemoglobin concentration, red blood cells (MCV), lymphocyte and monocyte counts 
were significantly increased in the two groups while neutrophil, platelet, eosinophil and total 
white blood cell (WBC) counts were significantly decreased, there was no significant 
differences between the two groups (Figure 2).
Gene expression profiles in Maf- and Mtb-infected patients pre- and post-treatment
The analysis strategy to ascertain differences in gene expression between Maf- and Mtb-
infected patients pre- and post-treatment is summarized in Figure 3. Firstly, we combined 
the 2 groups and performed a comparison between pre- and post-treatment time points. We 
found that over 6000 genes were differentially expressed between the pre- and post-
treatment, with enrichment in Gene Ontology (GO) terms related to changes in metabolism 
and immune processes. Secondly, gene expression profiles in peripheral blood from all 
patients were compared pre- and post-treatment in direct group wise comparisons (Figure 3). 
Prior to treatment, gene expression profiles in Maf- and Mtb-infected patients were highly 
similar, with only 51 genes showing significant differential expression. Strikingly, after 
completion of the standard 6-month anti-TB chemotherapy, over 1600 gene probes, 
representing ~1400 annotated transcripts, were differentially expressed between Maf- and 
Mtb-infected patients (see Supplementary Table 1A for complete list); two thirds of these 
genes were significantly higher, while one-third was lower expressed in Maf- compared with 
Mtb-infected patients (Supplementary Figure 1). Very few genes (n=13) showed significant 
differences in the interaction between treatment time points and mycobacterial infecting 
lineage.
Differential expression post-treatment is associated with nuclear transcription factor 
HNF4A
A possible explanation for this differential gene expression between the groups after 
treatment could be incomplete resolution of pathology in one of the groups. We checked for 
an overlap with genes in the disease signature (i.e. the > 6.000 genes differentially expressed 
between pre- and post-treatment). Only 175 annotated transcripts were present in both 
comparisons and these did not relate to any GO enrichment, indicating that the differential 
gene expression post-treatment might not be a residual disease signature.
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To further understand the biological processes associated with the differentially expressed 
genes between the two groups post-treatment, a pathway analysis was performed using 
Ingenuity Pathway Analysis (IPA) software. Ingenuity canonical pathway analysis revealed 
high enrichment in general metabolic processes such as the pentose phosphate pathway 
(Figure 4A). In addition, a network of immune response and metabolic disease-related 
genes, including Ras, MYBL1, SERBP1, SHOC2, PDS5A, RBBP4, Hat and TMOD3 showed 
an overall higher expression in Maf- than in Mtb-infected patients (Figure 4B). Further 
analysis of the gene set revealed a highly significant enrichment (p= 1.0−7) for the upstream 
regulator hepatocyte nuclear factor 4 alpha (HNF4α), which regulates almost 200 genes (~ 
15% of genes) in the list of differentially expressed genes between the two groups post-
treatment (Supplementary Table 1B).
Serum metabolic profiles of Maf- and Mtb-infected patients
Given that the differentially expressed genes were predominantly those involving metabolic 
pathways, we investigated the serum metabolic profiles of the same patients. In general, 
there was no statistically significant difference in the serum metabolites between Mtb and 
Maf-infected patients at either pre- or post-treatment time points. In accordance, analysis of 
all patients combined showed that the abundances of 51 compounds were significantly 
different between the pre- and post-treatment time points (Supplementary Table 2). 
However, Maf-infected patients showed less pronounced differences than Mtb-infected 
patients between pre- and post-treatment (Figure 5). Mannose was the only metabolite that 
showed significant differences between pre- and post-treatment in Maf-infected patients. 
The hypergeometric test for pathway enrichment amongst the 51 compounds showed a 
statistically significant enrichment of the “carbohydrate” category (p < 0.03, 3.3-fold 
enrichment).
Correlation between peripheral blood metabolites and gene expression profiles
We analyzed for correlations between the serum metabolites and gene expression to identify 
possible biological relationships. To obtain a conservative and robust list of potential 
correlations between metabolic and transcriptomic profiles, we included only 25 % of genes 
with the highest interquartile range (IQR) and metabolites with an IQR higher than 0, 
resulting in 505 metabolites. Only intra-group correlations between peripheral blood 
metabolites and gene expression were considered so as to remove the effect of the inter-
group correlations. We fitted a linear regression model for each of the data with the groups 
(pre- and post-treatment) as the predictor, and used the residuals from these models to 
calculate Spearman rank correlation coefficients. We found that among the 21 strongest 
correlations (with correlation coefficient rho > 0.65), 8 corresponded to correlations between 
particular genes and the metabolite arabinose, which was present at significantly higher 
levels in patients from the pre-treatment group. Also, 4 of the strongest correlations were 
between X- or Y-chromosome-linked genes and steroid hormones. To obtain a better 
understanding of the biological link between arabinose and gene expression profiles, we 
performed GO enrichment analysis (using GOrilla) of genes sorted according to their 
absolute correlation with arabinose. Interestingly, we found a significant enrichment in 
genes involved in bacterial defense and acute inflammatory responses (Supplementary 
Figure 2).
Tientcheu et al. Page 4
Genes Immun. Author manuscript; available in PMC 2016 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Discussion
In this study, we investigated the differences in TB pathogenesis and response to drug 
treatment between two MTBC lineages, Maf and Mtb, infecting a sympatric host population 
by comparing peripheral blood gene expression and serum metabolic profiles before and 
after anti-TB chemotherapy. Discovery and exploitation of MTBC lineages-specific host 
biomarkers could further our understanding of TB pathogenesis as well as improve 
diagnosis, treatment or vaccine development for TB. Peripheral blood gene expression 
profiles were not different between Maf- and Mtb-infected patients pre-treatment but 
differed significantly post-treatment, and these were predominantly associated with immune 
responses and metabolic diseases. Intriguingly, the hepatocyte nuclear factor 4 alpha 
(HNF4α) regulated about 15% of the genes differentially expressed between the groups 
post-treatment. The serum metabolic profiles were similar between Maf- and Mtb-infected 
patients both pre- and post-treatment, but significantly different between pre- and post-
treatment, particularly in Mtb- than in Maf-infected groups.
Although both groups had very similar clinical presentations at baseline and no significant 
interaction between treatment and lineages was found, the machine learning models 
performed better for Mtb samples than Maf samples, suggesting that a better clinical 
resolution of the disease was achieved for Mtb-infected groups. The similarity in peripheral 
blood transcriptomic and metabolic profiles before treatment suggests uniformity in host 
responses after succumbing to infection, irrespective of the infecting lineage of MTBC. This 
is also supported by the similar clinical scores and activated T cells proportions between the 
groups previously described before start of treatment.17 Differences observed after 
completing 6-month treatment could reflect differences in the mycobacterial lineage 
response to anti-TB drugs and/or host immune response for recovery. 19,23,26 Although we 
did not identify a strong association or enrichment of inflammatory response-related genes, 
clinical data suggest slower recovery in Maf-infected patients. The poor resolution of CXR, 
and higher proportion of activated T cells17 following completion of anti-TB treatment in 
Maf-infected patients likely indicate persistence of the bacilli, possibly due to lower in-vivo 
drug sensitivity or inability of the host anti-TB immune response to have resolved within 
this period post-treatment or persistence of the bacilli in Maf-patients. The similarity of the 
peripheral blood cell counts between the two groups both pre- and post-treatment, 
suggesting that differences in transcriptomic and metabolic profiles might be functional 
rather than structural support that it takes longer time for the inflammatory responses in Maf 
to resolve.
HNF4α is a highly conserved member of the nuclear receptor superfamily expressed in 
liver, kidney, intestine and pancreas of mammals,28 and was found to regulate about 15% of 
the genes differentially expressed between the groups post-treatment in this study. It is 
considered a global regulator of hundreds of genes involved in intermediary metabolism, 
liver functions, inflammatory responses,28,29 and glucose, fat and drug metabolism.30 
Further, HNF4α is directly linked with different human diseases including diabetes, a major 
risk factor for TB,31,32 hepatitis B virus infections, atherosclerosis and hemophilia.33,34 
Thus, our results suggest that Maf-infected patients may have a subclinical metabolic or 
liver dysfunction that is associated with susceptibility to this relatively low virulent lineage 
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of MTBC. Moreover the role of HNF4α in xenobiotic and drug metabolism28 may support 
defective anti-TB drug metabolism and in-vivo efficacy leading to poor clearance of the 
bacilli. HNF4α also interacts closely with liver X receptor (LXR), another master regulator 
of lipid metabolism,35 which contributes to the protective immune response against Mtb.36 
A recent study showed that polymorphisms in the lxr gene are associated with increased 
susceptibility to TB in a Chinese population.37 Taken together, our results indicate that 
HNF4A is potentially associated with susceptibility to TB. Further research is needed to 
contest this hypothesis.
Interestingly, the metabolites that changed significantly following treatment are consistent 
with those previously identified to differ between active TB and healthy individuals.38 The 
difference in the pattern of changes of these metabolites between the time points in each 
group suggests subtle differences in the response of the MTBC lineages to anti-TB 
treatment. For example, the serum tryptophan concentration significantly increased in Mtb-
infected patients after treatment, while this effect was not detected in Maf-infected patients. 
Serum tryptophan concentration has been shown to be lower in active TB patients compared 
to treated patients and healthy controls, and has been suggested as a prognostic marker for 
pulmonary TB.39 Tryptophan is actively degraded into kynurenine by indoleamine 2, 3-
dioxygenase, which is induced by the bacteria during active TB,40 thereby driving an 
increase in kynurenine abundance with a reverse scenario in healthy individuals.38,39 
However, no differences were detected in kynurenine concentration post-treatment in either 
group probably because kynurenine metabolism constitutes only a small part of tryptophan 
catabolism.41 In contrast to the transcriptomic data, the metabolic profiles did not show any 
significant differences between the two groups post-treatment or any significant interactions 
between treatment (pre and post) and bacterial lineage.
The concentration of serum arabinose, a pro-inflammatory molecule, which significantly 
decreased in Mtb compared to Maf patients following treatment, showed higher correlation 
with genes associated with host defense. In addition, xylitol shown to have anti-microbial 
activity against S. pneumonia and Influenza virus in animal models,42,43 was more 
significantly decreased in Maf than Mtb-infected patients post-treatment. The differences in 
these metabolites are indicative of variance in the resolution of pro-inflammatory responses 
between Maf and Mtb after treatment.44
The weak or absence of statistical significance in some comparisons in our study may be in 
part due to the small group sizes. However, a number of important findings that could be 
further explored to get more understanding of the pathogenesis of TB have been identified in 
this exploratory finding.
Very few studies have investigated the impact of MTBC lineage differences on human host 
peripheral blood transcriptomic and metabolic profiles.12 Our study is among the first to 
address this question using clinical data and high-throughput techniques to compare host 
responses between Maf- and Mtb-infected patients on the global level. Changes in both 
peripheral blood cell transcriptomic and serum metabolomic profiles during treatment and 
differences in gene expression between the two groups after treatment, suggest that host-
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intrinsic differences contribute to TB susceptibility and/or differences in response to 
standard anti-TB therapy.
Methods
Ethics statement
Ethical approval for this study was obtained from The Gambian Government/Medical 
Research Council (MRC) Joint Ethics Committee in The Gambia, and the London School of 
Hygiene & Tropical Medicine Ethics Committee in the UK. Written informed consent was 
obtained from all study participants.
Study participants
The 26 sputum smear- and culture-positive TB patients included in this study were recruited 
at the TB clinic of the Medical Research Council (MRC) Unit, in The Gambia as previously 
described.17 All patients were HIV-negative with no history of previous TB disease and 
were consecutively enrolled before starting anti-TB treatment and followed-up at 6 months 
of treatment. All patients underwent a routine CXR that was analyzed as previously 
described,45 were treated according to the Gambian National Leprosy and Tuberculosis 
Programme treatment guidelines (2HRZE/4HR), and were sputum smear-negative post-
treatment. The infecting lineage genotype was determined using standard spoligotyping 
analysis, and by assessing the presence or absence of lineage defining large sequence 
polymorphisms (LSP) RD702 and TbD1, as previously described.17,46 Drug susceptibility 
tests for first-line anti-TB drugs were performed using the BACTEC MGIT 960 SIRE kit 
(Becton-Dickinson). All patients had fully drug-susceptible TB isolates at recruitment. At 
each time point, peripheral whole blood (2.5 mL) was collected from every patient in 
PAXgene tubes (PreAnalaytiX) and stored at −80 °C before processing. Serum samples 
were stored at −20 °C.
RNA extraction and microarray procedure
RNA was isolated from PAXgene tubes using the PAXgene blood RNA kit (PreAnalytix). 
RNA was labeled with the Fluorescent Linear Amplification Kit (Agilent Technologies) 
according to manufacturer’s instructions. Quantity and labeling efficiency were verified 
before hybridization of the samples to whole-genome 4×44k human expression arrays 
(Agilent) and scanned at 5 μm using an Agilent scanner. Microarray data comply with 
MIAME (minimal information about microarray experiment) guidelines and have been 
deposited in the Gene Expression Omnibus (GEO) database under accession # GSE62147.
Data and Statistical Analysis strategy
Analysis of the scanned images was performed with Feature Extraction software (version 
10.5.1, Agilent Technologies). Gene expression data were analyzed using Agilent’s 
GeneSpring software (version 12.1). Raw microarray data were quantiles normalized 
without baseline transformation. Metabolomic profiles and correlation analyses were 
performed using the R package Limma. We followed 2 main analysis strategies. First, 2-way 
ANOVA was used to analyze differences in expression between the groups of patients 
infected with Maf and Mtb at recruitment and post-treatment (Figure 3). This strategy 
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includes the analysis of differences in anti-TB treatment effect between Maf and Mtb-
infected patients. Second, moderated T-tests were applied for direct group wise 
comparisons, which may give a clearer picture of differences between patient groups (Maf 
and Mtb) at the time of recruitment or post-treatment. Benjamini-Hochberg correction for 
multiple testing was applied in all tests and corrected p-values < 0.01 were considered 
significant. Since no gene expression or metabolomics data on similar patients groups are 
available, no power estimates could be performed to test the used parameters on our group 
sizes. Enrichment analysis of differentially expressed genes based on Gene Ontology (GO) 
terms was performed using the web-based tool GOrilla (http://cbl-gorilla.cs.technion.ac.il). 
Ingenuity Pathway Analysis (IPA) was used to study the gene interaction network and 
enrichment of upstream regulators of expressed genes. Continuous clinical data were 
compared between the groups using a two-tailed Mann Whitney U test and Wilcoxon 
matched-pairs signed-rank test, while categorical data was compared using a Fisher’s exact 
test.
Serum metabolic profiling procedure
Metabolites in serum from the study group were analyzed using non-targeted mass 
spectrometry (MS) analysis, which was performed at Metabolon, Inc (North Carolina, USA) 
as described previously.47 Metabolites were identified by automated comparison of ion 
features in the experimental samples to a reference library of chemical standard entries, 
including retention time, molecular weight (m/z), preferred adducts, and in-source fragments 
as well as associated MS spectra. Identification of known chemical entities is based on 
comparison to metabolomic library entries of purified standards. Statistical analysis of 
metabolomic data was done using the R package limma.48 Machine learning was performed 
using the Random Forest package from R.49
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Figure 1. Changes in clinical parameters in Maf- and Mtb-infected patients pre- and post-
treatment
Line graphs representing variation of weight (A), body mass index (BMI; B), skinfold 
thickness (C) and chest X-ray score (CXR score; D) in Maf- (circle) and Mtb- (triangle) 
infected patients pre- and post-treatment. P-values shown derived using a Wilcoxon 
matched-pairs signed rank test.
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Figure 2. Comparison of peripheral blood cell populations between Maf- and Mtb-infected 
patients pre- and post-treatment
Each dot represents an individual patient in the Maf- (circle) or Mtb- (triangle)-infected 
groups pre- and post-treatment. %: percentage of peripheral blood cells, MCV: mean 
corpuscular volume (red blood cells), WBC: white blood cell. The horizontal bars indicate 
median and interquartile responses. A two-tailed Mann Whitney U test was used for 
comparison between groups at each time point, and a two-tailed Wilcoxon matched-pairs 
signed-rank test for comparison between pre- and post-treatment results within each group. 
P-values for significant differences are shown.
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Figure 3. Analysis strategy of Maf- and Mtb-infected patients’ transcriptomic data
Circles represent the different groups at each treatment time point. Arrows indicate the 
different analytical comparisons described herein where a) is the comparison between the 
two lineages at each time point and b) the comparison within each lineage between 
recruitment and post-treatment time point.
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Figure 4. Ingenuity pathways analysis of differentially expressed genes between Maf- and Mtb-
infected patients post-treatment
(A) Bar chart shows gene enrichment in general metabolic processes and orange points 
represent ratio of significantly expressed genes calculated by dividing the number of genes 
in a given pathway that meet the cut-off criteria by the total number of genes that make up 
the pathway and that are in the reference gene set. The threshold is at p=0.05. (B) Shows the 
Ingenuity network containing immune response and metabolic disease-related genes that 
were differentially expressed between Maf- and Mtb- infected patients post-treatment. Genes 
that were higher expressed in Maf than in Mtb are depicted in red, those lower expressed in 
Maf in green.
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Figure 5. Some metabolites with statistically significant different serum concentrations between 
pre- and post-treatment time points
Changes in relative abundance in selected serum metabolites pre- (recruit) and post-
treatment in Maf- and Mtb-infected patients are shown. Each dot represents a patient. Stars 
indicate significant differences between profiles for each lineage separately (results from 
Wilcoxon rank sum test corrected for multiple testing (Benjamini-Hochberg); * Corr 
p<0.05), y-axis indicates normalized values (ion counts rescaled to median = 1).
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Figure 6. 
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Table 1
Demographic and clinical characteristics of M. africanum and M. tuberculosis patients
Maf Mtb p-value
n Positive (%) n Positive (%)
Number of cases a 12 1 (46) 14 14 (54)
Demographics
Age in years, median (range) 12 27.5 (19–58) 14 26 (15–79) 0.683
Sex (Female) 12 3 (25) 14 5 (36) 1.0
Ethnicity 12 14 0.452
 Mandinka 4 (33) 8 (57)
 Jola 2 (17) 2 (14)
 Other 6 (50) 4 (29)
Clinical characteristics
Duration of cough (>3 weeks) 12 11 (92) 14 11 (79) 1
Days of treatment prior recruitment 12 6 (0–21) 14 15 (0–21) 0.155
BMI, median (range)
 Enrolment 12 18.2 (17–22) 14 18.6 (13–32) 0.643
 6 months 10 18.2 (15–21) 12 19.1 (17–36) 0.092
Skinfold thickness mm median (range)
 Enrolment 12 7.3 (5–11) 14 8 (6–20) 0.289
 6 months 10 8.5 (5–20) 13 14 (6-23) 0.113
CXRc) Extent of disease 12 [10]b 14 [13] 0.673 [0.046]b
Minimal 3(25) [2(20)]b 2(14) [8(61)]b
Moderate 3(25) [5(50)]b 6(43) [2(15)]b
Severe 6(50) [2(20)]b 6(43) [0(0)]b
Maximum smear grade 12 14 0.012
 1 3 (25) 0 (0)
 2 6 (50) 3 (21)
 3 3 (25) 11 (79)
a
Total number of patients recruited = 26,
b[ ], 6-month CXR scores. Abbreviations: BMI, body mass index; CXR, chest X-ray; Maf, M. africanum; Mtb, M. tuberculosis
Genes Immun. Author manuscript; available in PMC 2016 January 01.
